- Home
- ATRA vs QNCX Comparison
ATRA vs QNCX Comparison
Compare ATRA & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATRA
- QNCX
- Stock Information
- Founded
- ATRA 2012
- QNCX 2012
- Country
- ATRA United States
- QNCX United States
- Employees
- ATRA N/A
- QNCX N/A
- Industry
- ATRA Biotechnology: Biological Products (No Diagnostic Substances)
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ATRA Health Care
- QNCX Health Care
- Exchange
- ATRA Nasdaq
- QNCX Nasdaq
- Market Cap
- ATRA 97.0M
- QNCX 85.9M
- IPO Year
- ATRA 2014
- QNCX 2019
- Fundamental
- Price
- ATRA $14.41
- QNCX $1.65
- Analyst Decision
- ATRA Strong Buy
- QNCX Strong Buy
- Analyst Count
- ATRA 3
- QNCX 6
- Target Price
- ATRA $21.00
- QNCX $8.00
- AVG Volume (30 Days)
- ATRA 52.1K
- QNCX 263.4K
- Earning Date
- ATRA 11-11-2025
- QNCX 11-12-2025
- Dividend Yield
- ATRA N/A
- QNCX N/A
- EPS Growth
- ATRA N/A
- QNCX N/A
- EPS
- ATRA 0.56
- QNCX N/A
- Revenue
- ATRA $188,667,000.00
- QNCX N/A
- Revenue This Year
- ATRA N/A
- QNCX N/A
- Revenue Next Year
- ATRA N/A
- QNCX N/A
- P/E Ratio
- ATRA $25.58
- QNCX N/A
- Revenue Growth
- ATRA 202.41
- QNCX N/A
- 52 Week Low
- ATRA $5.01
- QNCX $0.69
- 52 Week High
- ATRA $18.71
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- ATRA 68.37
- QNCX 56.09
- Support Level
- ATRA $13.12
- QNCX $1.59
- Resistance Level
- ATRA $14.78
- QNCX $1.68
- Average True Range (ATR)
- ATRA 0.84
- QNCX 0.06
- MACD
- ATRA 0.16
- QNCX 0.01
- Stochastic Oscillator
- ATRA 86.14
- QNCX 69.57
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.